Last updated: November 4, 2026
Mylan Pharmaceuticals Inc. is no longer an independent public company. Its operating business became part of Viatris Inc. when Mylan N.V. combined with Pfizer’s Upjohn business on November 16, 2020. Mylan remains relevant as a legal entity, ANDA holder, manufacturer, and historical commercial brand, but competitive analysis should focus on Viatris’s combined platform.
Viatris generated approximately $15.4 billion in 2023 net sales and competes across generics, complex generics, biosimilars, branded medicines, and specialty products.[1] Its main strengths are global regulatory scale, manufacturing breadth, established payer relationships, and experience commercializing difficult-to-copy products. Its main risks are price erosion, product divestitures, patent challenges, manufacturing concentration, and competition from Teva, Sandoz, Hikma, Amneal, Cipla, and Indian generic manufacturers.
What is Mylan Pharmaceuticals Inc.’s current corporate status?
Mylan Pharmaceuticals Inc. is a subsidiary-level operating and legal entity rather than a standalone public pharmaceutical company.
| Item |
Current position |
| Historical parent |
Mylan N.V. |
| Combination date |
November 16, 2020 |
| Current parent |
Viatris Inc. |
| Transaction |
Mylan combined with Pfizer’s Upjohn business |
| Core activities |
ANDA products, complex generics, manufacturing, commercialization |
| Public listing |
Viatris, Nasdaq: VTRS |
| Primary headquarters of parent |
Canonsburg, Pennsylvania |
| Strategic model |
Global generics and specialty pharmaceutical platform |
The transaction combined Mylan’s generic and biosimilar business with Upjohn’s established brands, including Lipitor, Viagra, Celebrex, and Lyrica in selected markets.[1] The resulting company has broader geographic coverage than Mylan had independently, but it also inherited a portfolio with substantial exposure to mature products and loss-of-exclusivity pressure.
Mylan Pharmaceuticals Inc. may still appear in FDA records, patent cases, ANDA filings, manufacturing records, and settlement agreements. Those references do not indicate that Mylan continues to operate as a separate publicly traded company.
How strong is Mylan and Viatris’s market position?
Viatris is one of the largest global pharmaceutical companies by volume of generic and off-patent medicine sales. It has a stronger global position than most regional generic manufacturers, although it does not have the growth profile of specialty-focused biotechnology companies.
Market-position comparison
| Company |
Primary strength |
Geographic scale |
Key competitive limitation |
| Viatris |
Broad generics, complex products, global commercial infrastructure |
High |
Mature portfolio and price erosion |
| Teva |
Large generic base and specialty medicines |
High |
Debt history, litigation, and restructuring |
| Sandoz |
Generic and biosimilar specialization |
High |
Separation from Novartis and portfolio transition |
| Hikma |
Injectables, branded generics, hospital products |
High |
Smaller global scale than Viatris |
| Amneal |
U.S. generics and specialty products |
Medium |
Less international reach |
| Cipla |
Respiratory, HIV, and emerging-market strength |
High |
Lower U.S. commercial scale |
| Dr. Reddy’s |
Complex generics and emerging markets |
High |
Product-specific regulatory exposure |
Viatris competes on scale, supply reliability, regulatory execution, and portfolio breadth. It is less dependent on a single blockbuster than a biotechnology company whose value rests on one or two innovative assets. The tradeoff is lower product-level margins and continuous exposure to tender pricing and generic substitution.
What products and therapeutic areas are protected by Mylan’s commercial and manufacturing capabilities?
Mylan built its position through conventional generics, complex dosage forms, respiratory products, injectables, transdermal systems, ophthalmic products, and specialty medicines.
Important legacy and Viatris-associated products include:
| Product or category |
Commercial relevance |
Competitive characteristic |
| EpiPen and authorized generic epinephrine auto-injector |
Historically important U.S. franchise |
Device, supply, and substitution complexity |
| Wixela Inhub |
Generic fluticasone propionate/salmeterol |
Combination inhaler and device barriers |
| Glatiramer acetate |
Multiple sclerosis therapy |
Complex formulation and injection product |
| Semglee |
Insulin glargine biosimilar |
Biologic manufacturing and interchangeability |
| Fulphila |
Pegfilgrastim biosimilar |
Injectable biologic |
| Ogivri |
Trastuzumab biosimilar |
Oncology biologic |
| Hulio |
Adalimumab biosimilar |
Immunology biologic |
| Cardiovascular generics |
High-volume base business |
Strong price competition |
| Ophthalmic and injectable products |
Hospital and specialty channels |
Manufacturing and quality barriers |
Viatris transferred its global biosimilars business to Biocon Biologics in a transaction that closed in 2022. The transaction had a total potential value of up to approximately $3.335 billion.[2] As a result, biosimilars remain part of Mylan’s historical competitive record but are no longer the same direct strategic asset within Viatris.
What FDA regulatory milestones define Mylan’s competitive position?
Mylan’s most important regulatory advantage has been its ability to obtain approvals for products that are more difficult to develop than standard immediate-release tablets.
Key FDA milestones
| Date |
Product |
Regulatory significance |
| 2017 |
Ogivri |
One of the first FDA-approved trastuzumab biosimilars |
| 2018 |
Fulphila |
Pegfilgrastim biosimilar approved by FDA |
| 2019 |
Wixela Inhub |
FDA approval of a generic fluticasone/salmeterol product |
| 2021 |
Semglee |
First interchangeable biosimilar insulin product approved by FDA |
| 2022 |
Viatris-Biocon transaction closing |
Biosimilars business transferred to Biocon Biologics |
Semglee’s interchangeability designation was particularly important because it allowed pharmacy-level substitution under applicable state law, subject to the rules governing interchangeable biologics.[3] The product demonstrated Mylan’s ability to navigate biologic comparability, device, manufacturing, and regulatory requirements.
The strategic value of such approvals is higher than the value of ordinary oral generics because fewer competitors may be capable of entering the market. That advantage can narrow over time as additional manufacturers complete development and gain regulatory approval.
What patents protect Mylan and Viatris products?
Mylan’s patent position is product-specific and generally rests on a combination of:
- Composition-of-matter patents for branded products acquired or commercialized through partnerships.
- Formulation patents for complex generics and biologics.
- Device patents for auto-injectors and inhalers.
- Manufacturing-process patents and trade secrets.
- Method-of-use patents.
- Regulatory exclusivity and market-entry settlements.
Mylan generally has not relied on a single proprietary platform patent comparable to the core patent estate of an innovative biotechnology company. Its competitive protection comes from portfolio scale, regulatory complexity, manufacturing know-how, and the ability to file and defend ANDAs.
What formulations are protected by Mylan-related patents?
The most important formulation and delivery barriers are found in:
- Inhaled products, where the active ingredient, device, particle size, dose-counter mechanism, and delivery performance must align.
- Injectable products, where sterility, formulation stability, container closure, and process controls create development risk.
- Ophthalmic products, where preservatives, viscosity, sterility, and delivery systems affect approval.
- Insulin products, where biologic comparability, device performance, and interchangeability standards increase development costs.
- Auto-injectors, where device design and human-factors requirements can generate patent and regulatory barriers.
For Wixela Inhub, the principal competitive barriers are not limited to the active ingredients fluticasone propionate and salmeterol. The inhaler device, powder formulation, dose delivery, and product-specific FDA requirements create a more difficult entry path than a conventional tablet.
For EpiPen, the active ingredient, auto-injector design, labeling, device operation, and manufacturing controls all affect competition. The core active-ingredient patent position is historical, but device and regulatory barriers have remained relevant to market entry.
When did Mylan products lose exclusivity?
Mylan’s portfolio includes both products that have long lost primary patent protection and products with later regulatory or device-based barriers.
| Product |
Primary exclusivity position |
Current competitive assessment |
| EpiPen |
Core drug patents expired before current generic competition |
Device execution and supply remain relevant |
| Wixela Inhub |
Entered after branded Advair exclusivity weakened |
Complex generic competition |
| Semglee |
Entered after key insulin glargine patent barriers weakened |
Biosimilar and interchangeable competition |
| Ogivri |
Entered after Herceptin patent and regulatory barriers weakened |
Multiple trastuzumab competitors |
| Fulphila |
Entered after Neulasta exclusivity weakened |
Biosimilar price competition |
| Glatiramer acetate |
Multiple patent disputes and generic approvals |
Established multi-source market |
Exact patent expiration dates depend on the specific patent, jurisdiction, pediatric extensions, terminal disclaimers, regulatory exclusivity, and settlement terms. The FDA Orange Book remains the controlling public source for listed patents covering approved small-molecule products.[4] Biosimilar products are generally not listed in the Orange Book in the same manner as small-molecule drugs.
Which companies are challenging Mylan and Viatris products?
The main competitive threats come from large generic companies and specialized developers of complex products.
U.S. competitors
- Teva Pharmaceuticals
- Sandoz
- Amneal Pharmaceuticals
- Hikma Pharmaceuticals
- Lupin
- Dr. Reddy’s Laboratories
- Zydus Pharmaceuticals
- Cipla
- Sun Pharma
- Organon in selected branded and women’s-health categories
Product-level competitive threats
Teva and Sandoz are the most direct large-scale competitors in U.S. generics and biosimilars. Hikma is particularly strong in injectables and hospital products. Amneal has expanded in complex generics and specialty pharmaceuticals. Indian manufacturers compete aggressively on cost, API access, and emerging-market reach.
For biosimilars, competition includes Samsung Bioepis, Celltrion, Amgen, Pfizer, Organon, Boehringer Ingelheim, Fresenius Kabi, and Biocon Biologics. The competitive significance of Biocon is heightened because it acquired Viatris’s biosimilars business.
What Paragraph IV challenges and patent litigation affect Mylan?
Mylan has historically used Paragraph IV certifications to challenge patents listed for reference drugs before expiration. This strategy can accelerate generic entry and create litigation leverage.
A Paragraph IV filing states that a listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation under the Hatch-Waxman Act. The first substantially complete ANDA applicant may receive 180 days of generic exclusivity in qualifying circumstances, although the value of that exclusivity depends on other filers, forfeiture events, settlements, and market conditions.[5]
Mylan’s litigation exposure has historically included:
- Challenges to patents covering branded drugs.
- Disputes over formulation and dosage patents.
- Device-related patent litigation.
- ANDA litigation involving complex generics.
- Biosimilar patent disputes under the Biologics Price Competition and Innovation Act.
Patent litigation is a strategic tool rather than a permanent moat. A successful challenge can create early-entry value, but litigation costs, launch-at-risk exposure, settlements, and possible damages can reduce expected returns.
What is the Orange Book status of Mylan products?
Mylan’s small-molecule products may be associated with Orange Book listings through the reference product, the generic applicant’s approval history, or patents relevant to the ANDA litigation record. An approved generic itself generally does not create an independent Orange Book patent estate equivalent to the brand’s listed patents.
The Orange Book is most relevant to:
- Reference-listed drug patents.
- ANDA certifications.
- Patent expiration and exclusivity analysis.
- 30-month litigation stays.
- Generic launch timing.
- Authorized-generic competition.
For biologics such as Semglee, Orange Book analysis is incomplete. The Purple Book, FDA biologics guidance, BPCIA patent-exchange procedures, and product-specific exclusivity rules are more relevant.[6]
How strong is Mylan’s patent estate?
Mylan’s patent strength is moderate at the corporate level and stronger for selected products.
| Dimension |
Assessment |
| Composition-of-matter patents |
Limited for a generic-focused company |
| Formulation patents |
Moderate to strong in selected complex products |
| Device patents |
Meaningful for inhalers and auto-injectors |
| Manufacturing know-how |
Strong but difficult to assess publicly |
| Regulatory barriers |
Strong in biosimilars and complex generics |
| Litigation capability |
Strong due to scale and experience |
| Portfolio diversification |
Strong |
| Long-term exclusivity duration |
Generally weaker than innovative biotech companies |
Viatris’s durable advantage is not primarily patent exclusivity. It is the combination of global manufacturing, regulatory infrastructure, supply-chain scale, market access, and product breadth.
What licensing deals and transactions shaped Mylan’s strategy?
The most important strategic relationships were:
- Mylan’s collaboration with Biocon for biosimilar development and commercialization.
- The Mylan-Upjohn combination that created Viatris.
- The transfer of Viatris’s biosimilar business to Biocon Biologics.
- Regional commercialization and licensing arrangements for branded and specialty products.
The Biocon relationship allowed Mylan to enter biologics without building the entire discovery and development infrastructure internally. The later divestiture shows a shift toward capital allocation, debt reduction, and portfolio simplification rather than continued ownership of a broad biosimilar platform.[1][2]
What generic launch scenarios exist for Mylan and Viatris products?
Four launch scenarios are most relevant:
- Single-generic entry: Mylan or Viatris gains substantial share before additional competitors arrive.
- Shared first entry: Several approved or settled applicants launch near the same date, reducing price and volume benefits.
- At-risk launch: A product launches before patent litigation is finally resolved, exposing the company to damages or injunction risk.
- Authorized-generic competition: The brand owner or a partner launches an authorized generic, reducing the value of independent generic entry.
For complex inhalers, injectables, ophthalmics, and devices, the practical launch date can be delayed by manufacturing validation, supply readiness, state substitution rules, payer contracting, and pharmacy stocking.
What revenue exposure does Viatris have to patent loss and generic price erosion?
Viatris has meaningful exposure to loss of exclusivity, but its global portfolio reduces dependence on one product. The principal financial risks are:
- Price compression after multiple generic entrants.
- Declining volumes for mature branded products.
- Reimbursement pressure in U.S. managed care and government channels.
- Manufacturing remediation or supply interruption.
- Divestiture of higher-growth assets.
- Reduced biosimilar contribution after the Biocon transaction.
Its 2023 net sales of approximately $15.4 billion provide scale, but revenue size should not be confused with high-quality exclusivity. Generic sales can remain large while margins decline rapidly after market entry by several competitors.[1]
What is the outlook for Mylan and Viatris?
Viatris’s strongest strategic path is to concentrate on complex generics, selected specialty products, emerging markets, and operational efficiency. The company is less differentiated in commoditized oral solids, where price competition is intense and switching costs are low.
The business has higher barriers in inhalation, ophthalmology, injectables, transdermal delivery, and selected biosimilar or biologic-related products. Its former biosimilars platform, however, is now owned by Biocon Biologics, which changes the competitive comparison.
For investors, licensors, and competitors, the main diligence issue is product-level execution rather than the Mylan name. The relevant questions are whether a product has multiple approved competitors, whether patents have been challenged, whether a device or formulation creates a meaningful barrier, and whether Viatris controls manufacturing capacity and market access.
Key Takeaways
- Mylan Pharmaceuticals Inc. is now part of Viatris and is not an independent public company.
- Viatris generated about $15.4 billion in 2023 net sales.
- The company’s strongest assets are global scale, complex generics, manufacturing, and regulatory execution.
- Its patent estate is product-specific and generally weaker than the estate of an innovative biotechnology company.
- Inhalers, injectables, ophthalmics, insulin products, and auto-injectors have higher entry barriers than standard tablets.
- Viatris transferred its biosimilars business to Biocon Biologics in 2022.
- Teva, Sandoz, Hikma, Amneal, Cipla, and Dr. Reddy’s are major competitive threats.
- Paragraph IV litigation and Orange Book analysis remain central for small-molecule products.
- Purple Book and BPCIA analysis are more relevant for biosimilars.
- The principal commercial risk is sustained price erosion after multiple generic entrants.
FAQs
Is Mylan Pharmaceuticals still a separate company?
Mylan Pharmaceuticals Inc. remains a legal and operating entity in certain FDA, manufacturing, and litigation records, but its parent business became part of Viatris in 2020.
Does Mylan still own a biosimilar business?
Viatris transferred its biosimilars business to Biocon Biologics in 2022. Historical Mylan biosimilar products remain relevant to competitive analysis, but the business is no longer owned by Viatris in its former structure.
Which Mylan product has the strongest formulation barrier?
Wixela Inhub has a stronger barrier than a conventional oral generic because it requires an inhalation device, dry-powder formulation, dose delivery, and product-specific FDA approval.
Are Mylan products listed in the FDA Orange Book?
Mylan ANDA products may appear in FDA approval records and may be involved in Orange Book patent disputes tied to reference drugs. The Orange Book primarily lists patents for approved reference drugs, not an equivalent independent patent estate for every generic product.
Which company is the closest competitor to Viatris?
Teva is the closest broad-based competitor by global generic scale. Sandoz is also a direct competitor, while Hikma and Amneal are stronger in selected injectable, complex-generic, and U.S. specialty segments.
References
- Viatris Inc. (2024). 2023 annual report. https://investor.viatris.com/financial-information/annual-reports-and-proxy-statements
- Biocon Biologics Ltd. (2022). Biocon Biologics completes acquisition of Viatris’ global biosimilars business. https://www.bioconbiologics.com
- U.S. Food and Drug Administration. (2021). FDA approves first interchangeable biosimilar insulin product. https://www.fda.gov/news-events/press-announcements/fda-approves-first-interchangeable-biosimilar-insulin-product
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- U.S. Food and Drug Administration. (2024). ANDA submissions: Refuse-to-receive standards and patent certification requirements. https://www.fda.gov/drugs
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
